InhaleRx Ltd: IRX616a IND Application Outcome
InhaleRx Ltd: Final Clinical Study Report Received, Phase 1 IRX-211
InhaleRx Ltd: Change of Director's Interest Notice - Sean Williams
InhaleRx Ltd: Significant Milestone - IND submitted to the FDA for IRX616a
InhaleRx Ltd: Mar24 Appendix 4C Cash Flow Report
InhaleRx Ltd: Mar24 Quarterly Activities Report
InhaleRx Ltd: Change of Registered Office Address
InhaleRx Ltd: Appendix 4G
InhaleRx Ltd: Corporate Governance Statement and Appendix 4G
InhaleRx Ltd: $500,000 Convertible Loan Facility
InhaleRx Ltd: Shareholder Townhall Webinar - Wed 20 Mar 2024 at 1.30pm
InhaleRx Ltd: Milestone achieved - Database Lock Phase 1 IRX211
InhaleRx Ltd: Dec23 Appendix 4C Cash Flow Report
InhaleRx Ltd: Dec23 Quarterly Activities Report
InhaleRx Ltd: IRX211 - Targeted Pain Indication Nomination - BTcP
InhaleRx Ltd: R & D Tax Incentive Funding Agreement
InhaleRx Ltd: Significant Milestone - Completion of IRX211 Phase 1 Trial
InhaleRx Ltd: Shareholder Webinar - 12pm AEDT on Wed 22 Nov 2023
InhaleRx Ltd: Clarification of claim against significant IRX shareholder
InhaleRx Ltd: Sep23 Appendix 4C
No Data